Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Simone RivoloManuela Di FuscoCarlos PolancoAmiee KangDevender DhandaMirko SavoneAristeidis SkandamisThitima KongnakornJavier SotoPublished in: PloS one (2021)
Apixaban was a dominant treatment strategy than VKA from both the Spanish payer's and societal perspectives, regardless of treatment strategy considered.